New Times,
New Thinking.

24 April 2013

SpaceX Grasshopper makes its highest flight yet

The Grasshopper made it 250m in the air, hovered, and landed back down.

By Alex Hern

SpaceX, the space transport company founded by former PayPal founder Elon Musk, just carried out its most successful test yet of it’s “Grasshopper” vertical take-off and landing system. In a short flight earlier this week, the rocket rose 250m in the air, hovered, and then returned to the ground:

The system is a testbed for one of SpaceX’s broader goals, developing “fully and rapidly” reusable rockets. Current generation launch vehicles are comprised of several stages, the majority of which either burn up in the atmosphere after use, or, at best, splash down in the ocean where they much be collected and repaired at great expense.

If the Grasshopper system – which consists of a modified version of the first stage tank of the company’s flagship Falcon 9 rocket, the first private vehicle to visit the International Space Station – scales up, it would allow the company to reuse rockets with little delay. That’s a crucial element to almost every plan for making fully private space travel economical, but there’s still a long way to go.

Select and enter your email address Your weekly guide to the best writing on ideas, politics, books and culture every Saturday. The best way to sign up for The Saturday Read is via saturdayread.substack.com The New Statesman's quick and essential guide to the news and politics of the day. The best way to sign up for Morning Call is via morningcall.substack.com
Visit our privacy Policy for more information about our services, how Progressive Media Investments may use, process and share your personal data, including information on your rights in respect of your personal data and how you can unsubscribe from future marketing communications.
THANK YOU

Content from our partners
Unlocking investment in UK life sciences through manufacturing
Data defines a new era for fundraising
A prescription for success: improving the UK's access to new medicines